Polyunsaturated Fatty Acids and Atherosclerosis: Insights from Pre‐Clinical Studies
Published on Jan 1, 2019in European Journal of Lipid Science and Technology1.852
· DOI :10.1002/ejlt.201800029
Atherosclerosis and its complications are responsible for more global deaths than any other disease. Atherosclerosis is a chronic inflammatory disease of medium and large arteries that can cause clinical complications such as myocardial infarction and cerebrovascular accidents. Current therapies against atherosclerosis mainly target the dyslipidemia associated with the disease and are associated with considerable residual risk for cardiovascular disease together with various side effects. In addition, the outcomes of clinical trials on many pharmaceutical agents against promising therapeutic targets have been disappointing. This has resulted in considerable recent interest on nutraceuticals in the prevention of atherosclerosis and as add‐on with current pharmaceutical therapies. However, nutraceutical research has considerably lagged those on pharmaceuticals on two key aspects, large clinical trials and mechanistic insights. The latter forms the focus of this review in relation to the potential beneficial actions of polyunsaturated fatty acids as identified from pre‐clinical studies.
Figures & Tables